Eli Lilly and Co. announced Thursday, Dec. 18 that its experimental daily GLP-1 pill, orforglipron, successfully helped ...

On the policy front, the U.S. Senate passed the Biosecure Act, legislation designed to limit federal reliance on certain foreign biotechnology companies viewed as national security risks. The measure ...

Novo Nordisk's application for CagriSema comes at the same time as competitor Eli Lilly's ask for its obesity drug orforglipron. Elsewhere, Merck & Co. and Pfizer succeeded in a bladder cancer study.

Eli Lilly (NYSE:LLY) is rapidly establishing itself as the leader in GLP-1 treatments for weight loss. Its Zepbound injection ...

Congress is leaving town for the holidays — and another year has gone by, with bipartisan pharmacy benefit manager legislation still on the flight deck.

The pharmaceutical sector's most intense rivalry is escalating. Eli Lilly has unveiled pivotal Phase 3 trial results for its ...

In November 2025, US President Donald Trump announced transformative actions to lower prescription drug costs and secure the ...

Eli Lilly and Novo Nordisk — the dominant players in obesity drug development — each submitted a new weight-loss drug to the ...

Distilling that complexity into a handful of trends has been no small task. What follows is not a definitive forecast, but ...

Eli Lilly stock hits a 90+ Quality score. BofA calls LLY underpriced, citing major growth ahead for its oral obesity drug.

Lilly has now submitted a new drug application (NDA) for orforglipron to the FDA for use in adults with obesity.

The pills are expected to cost much less then shots of blockbuster drugs like Zepbound and Wegovy. Mr. Funk was the managing ...